GLP-1 Agonists Are Quietly Reducing Addiction Hospitalizations, But Only While Patients Take Them
A recent study indicates that GLP-1 receptor agonists, commonly used for weight loss, are associated with reduced hospitalizations for substance use disorders. However, the protective effect for general substance use disorders disappears once the medication is discontinued, suggesting a complex neurological mechanism.
Why it matters
This research highlights a potential secondary medical application for GLP-1 drugs, which could revolutionize addiction treatment protocols.
What should we do with a drug that appears to treat addiction without being designed to?
That question sharpened for me when I read the new Lancet Psychiatry Swedish register-based study on GLP-1 receptor agonists and substance use disorder hospitalizations. The researchers used a within-individual design, following the same patients across periods of GLP-1 treatment and non-treatment, which is exactly the right method to strip out confounding. The signal was unambiguous: GLP-1 treatment was associated with meaningfully lower rates of alcohol use disorder and substance use disorder-related hospital admissions. And then came the detail that should rearrange how the field thinks about this class of drugs. After discontinuation, the protective association persisted for alcohol use disorder through the first 182 days. For substance use disorder broadly, it did not.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in